List view / Grid view
European Pharmaceutical Review has brought you the most up-to-date and relevant pharmaceutical science for the past 21 years. This anniversary supplement brings you a selection of topical views from across the industry, reviewing progress over that time, as well as looking to the future.
Major market players across the US are upping investments in research to innovate on treatment methods and improve ophthalmic drugs action...
10 May 2017 | By Niamh Marriott, Junior Editor
This follows the initiation of the Phase IIb trial by Conatus evaluating emricasan in patients with decompensated liver cirrhosis caused by NASH...
8 May 2017 | By Niamh Marriott, Junior Editor
Aptar Pharma’s dispensing technologies combined with Kali Care’s smart sensors, data analytics and cloud services will make clinical trials more efficient.
21 April 2017 | By Niamh Marriott, Junior Editor
Allergan will collaborate with TARGET PharmaSolutions, a clinical data company focused on real world evidence, on its TARGET-NASH study.
20 April 2017 | By Niamh Marriott, Junior Editor
Novartis has entered into a clinical trial agreement with Allergan to conduct a Phase IIb study, involving the combination of a Novartis’ FXR agonist...
European Pharmaceutical Review has been keeping the industry informed for 21 years and continues to bring insights into current and emerging technologies, contributions from recognised figures in the life science community and of course, the latest and most up to date news. To celebrate our success, we will be counting down…
5 December 2016 | By Niamh Louise Marriott, Digital Editor
The XEN Glaucoma Treatment System reduces intraocular pressure in patients and is indicated for the management of refractory glaucomas...
28 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Results of a Phase 2b trial of relamorelin, Motus' ghrelin agonist, for the treatment of gastroparesis in diabetics has led to Allergan acquiring Motus...
3 October 2016 | By Niamh Louise Marriott, Digital Content Producer
MEDI2070 is an IL-23 monoclonal antibody currently in a Phase IIb trial for Crohn’s disease (a chronic inflammatory disease of the intestines) and is...
26 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Trubberzi is an oral medication taken to relieve the main symptoms of irritable bowel syndrome with diarrhoea (IBS-D) in adults...
20 July 2016 | By Victoria White, Digital Content Producer
The US Food and Drug Administration (FDA) has approved an expanded label for Namzaric.
7 June 2016 | By Victoria White, Digital Content Producer
Byvalson is the first and only fixed-dose combination (FDC) of a beta blocker (BB) and angiotensin II receptor blocker (ARB) available in the US...
1 June 2016 | By Victoria White, Digital Content Producer
Allergan and Medicines360 are to donate 10,000 units of Liletta to the CDC Foundation in response to the Zika virus outbreak in Puerto Rico...
9 May 2016 | By Victoria White, Digital Content Producer
Allergan and Richter have announced positive results from Venus I, evaluating the efficacy and safety of ulipristal acetate in women with uterine fibroids...
